PUNE, India, February 23, 2017 /PRNewswire/ --
According to a new market research report "Influenza Diagnostics Market Test type (Traditional (Rapid Influenza Detection Test, Viral Culture, DFA, Serology Test), Molecular (RT-PCR, NASBA, LAMP, SAMBA)), End user (Hospital, Clinic, Reference lab, POC, Home Care Agency) - Global Forecast to 2021" published by MarketsandMarkets, the market is expected to reach USD 767.4 Million by 2021 from USD 508.0 Million in 2016, at a CAGR of 8.6% from 2016 to 2021.
Browse 91 market data Tables and 33 Figures spread through 127 Pages and in-depth TOC on "Influenza Diagnostics Market"
Early buyers will receive 10% customization on this report.
The report provides a detailed overview of the major drivers, restraints, opportunities, and threat impacting the Influenza Diagnostics Market along with the estimates and forecasts of the revenue and market share analysis. The increasing prevalence of influenza, growth in research funding for influenza diagnostics, and rising demand for faster diagnosis and control of influenza are the major factors that are expected to drive the growth of this market in the coming years. Also, advancements in technologies such as PCR and proteomics and significant growth prospects in developing countries are expected to offer growth opportunities for players in the Influenza Diagnostics Market.
The Influenza Diagnostics Market is segmented on the basis of test type, end user, and region. On the basis of test type, the market is segmented into traditional diagnostic tests and molecular diagnostic tests. The traditional diagnostic tests segment is further divided into rapid influenza detection tests (RIDT), viral culture, direct fluorescent antibody (DFA) tests, and serological assays. The molecular diagnostic tests segment is divided into RT-PCR, nucleic acid sequence-based amplification (NASBA) tests, loop-mediated isothermal amplification-based assays (LAMP), simple amplification-based assays (SAMBA), and other tests (microarray-based approaches and nucleic acid sequencing approaches). Among these, the traditional diagnostic tests segment is expected to account for the largest share of the global Influenza Diagnostics Market in 2016.
On the basis of end user, the market is segmented into hospitals/clinical laboratories, reference laboratories, and other end users (point-of-care testing, local public health laboratories, home health agencies, and nursing homes). The hospitals/clinical laboratories segment is expected to account for the largest share of the market in 2016. The large share of this segment can be attributed to the fact that most influenza disease diagnostic tests are carried out in hospitals and clinical laboratories, as these tests are highly complex in nature and require the use of specialized instruments.
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=240573338
On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, and RoW. The European market is expected to account for the largest share of the global Influenza Diagnostics Market in 2016. The large share of this segment is due to the increased prevalence of influenza disease and technological advancements in this region.
The prominent players in the Influenza Diagnostics Market are Thermo Fisher Scientific (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Quidel Corporation (U.S.), Becton, Dickinson and Company (U.S.), DiaSorin (Italy), SA Scientific (U.S.), and Luminex Corporation (U.S.).
Browse Related Reports:
Molecular Diagnostics Market by Application (Infectious Disease (HIV, HBV, TB), Oncology, Genetics, Microbiology), Technology (PCR, Hybridization, DNA Sequencing), End User (Hospitals, Laboratory), Product & Service (Reagent, Software) - Forecast to 2021
Respiratory Diagnostics Market by Product & Service (Instruments/Devices, Kits/Reagents), Test Type (Pulmonary Function Test, Imaging Test), Disease (TB, Lung Cancer, COPD), End User (Reference Laboratories, Physician Offices) - Global Forecast to 2021
MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets